CELLSCRIPT Revenue and Competitors

Madison, WI USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CELLSCRIPT's estimated annual revenue is currently $5.1M per year.(i)
  • CELLSCRIPT's estimated revenue per employee is $155,000

Employee Data

  • CELLSCRIPT has 33 Employees.(i)
  • CELLSCRIPT grew their employee count by 3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.8M1820%N/AN/A
#2
$1.9M1233%N/AN/A
#3
$1.4M9-31%N/AN/A
#4
$4.2M278%N/AN/A
#5
$5.2M670%$45.5MN/A
#6
$1.7M1157%N/AN/A
#7
$1.4M980%N/AN/A
#8
$0.9M6-33%N/AN/A
#9
$16.3M10521%N/AN/A
#10
$0.9M620%N/AN/A
Add Company

Our mission at CELLSCRIPTâ„¢ is to provide the best technologies and products pertaining to RNA for translation in cells to facilitate scientific discovery, for clinical research and for therapeutics. Available products include kits for in vitro transcription, 5' RNA capping using either a cap analog or capping enzymes, 3' RNA polyadenylation, as well as all-in-one kits for making capped, poly(A)-tailed mRNA for translation in cells. Contact CELLSCRIPTâ„¢ to discuss kits for making research or therapeutic grades of mRNA or custom manufacturing of an appropriate grade and scale of RNA for your project. Visit our website for more information at cellscript.com

keywords:N/A

N/A

Total Funding

33

Number of Employees

$5.1M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CELLSCRIPT News

2022-04-19 - Visual Dispensing Machine Market Size, Scope And Forecast ...

Omni cell, Script Pro, Bib Ophthalmic Instruments, Dispense Works, Shenzhen XINJI Intelligent Device. This Visual Dispensing Machine Market...

2022-04-13 - Visual Dispensing Machine Market Size And Forecast | Omni ...

Omni cell, Script Pro, Bib Ophthalmic Instruments, Dispense Works, Shenzhen XINJI Intelligent Device. The report provides a good overview of the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.5M33-6%N/A
#2
$4.3M333%N/A
#3
$5.3M336%N/A
#4
$5.5M33-11%N/A
#5
$3.8M333%N/A